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Knockout mice lacking the P2X1 receptor appear
normal, but fail to breed. Analysis of these mutant mice
clearly shows that purinergic co-transmission has a
physiological role in the vas deferens. These findings
also raise the possibility of developing non-hormonal
ways of regulating male fertility.
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Over 50 years ago, von Euler confirmed the identity of nora-
drenaline as the neurotransmitter released from sympathetic
nerve terminals. With time, however, it became apparent
that not all the effects of autonomic nerve stimulation could
be accounted for by the actions of noradrenaline and acetyl-
choline, and this led to the concept of ‘non-adrenergic and
non-cholinergic’ autonomic neurotransmission. Subse-
quently, it was proposed that ATP might act alongside nora-
drenaline and acetylcholine as a neurotransmitter released
from autonomic postganglionic neurons [1]. 
At first, this ‘purinergic’ hypothesis was not universally
accepted. But the weight of evidence has grown over the
years, with the demonstration of inter-neuronal purinergic
synapses in the brain [2] and myenteric ganglia [3], and
the cloning of specific purinergic receptors (see [4] for
review). Nevertheless, the physiological importance of the
purinergic component of co-transmission is not always clear.
The latest findings from the work of Mulryan et al. [5] have
provided hard evidence for an important physiological role
for purinergic transmission, at least in the vas deferens of
the mouse. They have demonstrated that purinergic neu-
rotransmission in the vas deferens plays a vital role during
copulation, ensuring high numbers of sperm are incorpo-
rated into the semen prior to ejaculation. 
A major problem in demonstrating purinergic co-transmis-
sion conclusively has been the lack of potent and selective
antagonists. Mulryan et al. [5] circumvented this problem
by using genetic manipulation to produce ‘knockout’ mice
lacking the gene for the P2X1 receptor. The only apparent
effect of this gene deletion was a 90% reduction in the fer-
tility of the male animals, which resulted from a low sperm
count in the ejaculated semen. Thus mutant females did
not become pregnant when mated with mutant males, but
normal rates of conception were observed when they
mated with wild-type or heterozygous males. 
The sperm from the mutant male mice were, however,
viable and able to fertilize ova in vitro. Mulryan et al. [5]
have therefore suggested that the selective pharmacologi-
cal blockade of P2X1 receptors should produce a similar
effect, and might thus provide the means for developing a
non-hormonal male contraceptive pill. If this approach is
successful, treatment could be effective in days or even
hours, unlike the protracted hormonal treatments at
present under evaluation [6]. Indeed, one could envisage a
product, perhaps a sublingual tablet or spray, which would
produce its effect within 30 minutes and could thus be
used on an ‘as required’ basis in a similar way to the anti
impotence drug Viagra.
The vas deferens is responsible for both the storage of
mature spermatazoa and for dispensing sperm into the
urethra to be combined with the other components of
semen prior to ejaculation. Stimulation of the vas deferens
with a train of electrial pulses gives rise to a biphasic con-
traction, consisting of an initial transient component which
declines to a more sustained plateau. The sustained
component of the response is blocked by α-adrenoceptor
antagonists, such as prazosin, while the transient compo-
nent is abolished by α,β-methylene-ATP, which acts to
desensitize the purinergic P2X receptors (Figure 1). The
combination of desensitization by α,β-methylene-ATP and
blockade of α1 receptors with prazosin completely abol-
ishes the response to nerve stimulation. The physiological
significance of these two components of the response is
now more clear. The fast purinergic component of the con-
traction is required to coordinate the rapid emission of
sperm into the urethra prior to ejaculation, while the sus-
tained noradrenergic contraction presumably prevents any
reflux into the vas deferens during ejaculation.
Receptors for extracellular ATP can been divided into two
categories: P2X receptors, which are ligand-gated ion
channels involved in fast signaling; and P2Y receptors,
which couple via heterotrimeric G proteins to a number of
different biochemical pathways. Seven different P2X
receptor subunits, P2X1–7, have been identified by molec-
ular cloning techniques. The number of subunits needed
to combine together to form a functional receptor is still
not clear. It is, however, known that while identical
subunits can co-assemble to form homomeric receptors,
some subunits will assemble with other members of the
family to form heteromeric receptors with novel properties
(see [4]). Molecular and immunohistochemical studies
suggest that the predominant isoform present on smooth
muscle cells is the P2X1 receptor. Furthermore, electro-
physiological and pharmacological studies have shown great
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similarity between the receptors present in smooth muscle
and P2X1 receptors expressed in recombinant systems.
In many early studies, desensitization of P2X receptors
was the most effective way of abolishing responses.
Subsequently, a number of antagonists including suramin,
reactive blue 2 and pyridoxalphosphate-6-azophenyl-2′,4′-
disulphonic acid (PPADS) were discovered. These com-
pounds lack potency and selectivity, however, and while
effective on isolated cells, they are usually much less
effective in intact tissues or in vivo. More recently TNP-
ATP and Ip5I have been found to be very potent antago-
nists at some subtypes of P2X receptor [7,8], although
again they appear to be much less active in intact tissues.
The increasing interest of pharmaceutical companies in
purinoceptor pharmacology should lead to the develop-
ment of a new generation of antagonists, with greater
potency, selectivity and activity in vivo.
Will a P2X1 antagonist work as a contraceptive in man?
The idea of a P2X1 receptor antagonist acting as a non-
hormonal male contraceptive is very attractive, but the
effectiveness of such a drug in man is by no means certain.
There is considerable species variation in the properties,
distribution and physiological role of P2X receptors. For
example, the neurogenic contraction of the urinary
bladder of the rat involves a large purinergic component,
while in healthy humans it is almost entirely cholinergic
(see [9]). The relative importance of purinergic transmis-
sion in the human vas deferens in vivo is far from clear.
While early in vitro studies failed to demonstrate a clear
purinergic component in the human vas deferens, it
should be remembered that these experiments were
carried out on tissue samples obtained from elective
vasectomy, and probably came from the more epidymal
end of the organ. In the rat, the purinergic component of
the neurogenic response is much greater in the prostatic
than epidymal region of the tissue. 
In a more recent study of the human vas deferens, a non-
adrenergic component was identified [10]. A considerable
part of the observed contraction was, however, resistant to
the sodium channel blocker tetrodotoxin, indicating that it
resulted from the direct stimulation of the smooth muscle.
Thus, if there is a purinergic component, it may be quite
small. On the other hand, oligospermia is not a recognized
side effect of treatment with α1 antagonists such as pra-
zosin, which might be an indication that non-adrenergic
neurotransmission is important for the emission of sperm
in man. Thus, there is at present considerable uncertainty
in the extrapolation from experimental animals to human
clinical practice. It may transpire that a combination of a
P2X1 and an α1 antagonist is required to inhibit emission
sufficiently to produce infertility in man.
Would there be side effects? 
P2X1 receptors are quite widely distributed on smooth
muscle cells, including those of blood vessels and the
urinary tract. Furthermore, messenger RNA for the P2X1
receptor has been detected in autonomic and sensory
ganglia and in the spinal cord. But evidence for func-
tional P2X1 receptors in neurons is still lacking. With
such a widespread distribution of P2X1 receptors, one
might anticipate that the use of a selective antagonist
would produce unwanted effects. Mice lacking these
receptors are described as generally healthy, however,
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Figure 1
Neurotransmission in the vas deferens. When the nerve action
potential invades the terminal varicocities, vesicles containing the
neurotransmitters noradrenaline (NA) and adenosine 5′-triphosphate
(ATP) exocytose their contents into the junctional cleft between the
axon and the smooth muscle cells. ATP binds to P2X1 receptors
(which are ligand-gated ion channels) to produce a rapid
depolarization (the excitatory junction potential), giving rise to a rapid,
though short-lived, contraction. Noradrenaline activates α1 receptors to
produce a slower but more sustained contraction through the release
of Ca2+ from intracellular stores. The mechanical response of the vas
deferens to electrical field stimulation (EFS) with trains of electrical
pulses varies slightly between species and with the stimulation
frequency. In general it consists of a rapid contraction which quickly
reaches a peak and then subsides to a lower level. When the α1
receptors are blocked by the antagonist prazosin, the time course of
the quickly activating and rapidly declining purinergic response is
revealed, while desensitization of the P2X1 receptors by the stable
ATP analogue α,β-methylene-ATP exposes the slower and more
sustained response mediated by noradrenaline. Combination of both
treatments completely abolishes the response to nerve stimulation.
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with no evidence of increased mortality in utero, but a
slight elevation in systolic blood pressure. 
While the apparent health of  P2X1 receptor-deficient
mice might imply that purinergic systems are unimpor-
tant, a more likely explanation is that there are changes in
other, parallel neurotransmitter systems which compen-
sate for the lack of purinergic signaling. For example, in
the P2X1 knockout mice, the sensitivity of the vas defer-
ens to noradrenaline is enhanced, leading to an increase in
the size of the noradrenergic component of the response
to nerve stimulation [5]. The effects of acute treatment
with a selective P2X1 antagonist may be quite different.
One might predict in the absence of up-regulation of other
transmitter systems, there would be both a greater contra-
ceptive efficacy and more side effects.
Our understanding of native P2X receptors has been
hampered by the lack of good pharmacological tools, and
while growing rapidly it is still relatively naïve. Some P2X
receptors are heteromeric, incorporating different P2X
subunits. Furthermore, some of the subunits occur as
splice variants, thus increasing further the scope for mole-
cular and pharmacological diversity. An additional level of
complexity arises from observations that, in some tissues,
more than one type of P2X receptor are present on the
same cell [11,12]. With this great potential for diversity
amongst native P2X receptors, there may well be scope for
P2X antagonists specific for the receptors present on the
vas deferens with minimal side effects.
In conclusion, the application of molecular genetics to the
field of purinoceptor research has provided conclusive
evidence for an important physiological role for purinergic
signaling in the mouse, and raises the possibility of a novel
approach to the regulation of male fertility. Whether this
approach can be developed into an effective clinical treat-
ment remains to be seen.
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